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ABSTRACT  24 
Objective: Hepatitis D virus (HDV) is a circular RNA virus co-infecting hepatocytes with 25 
hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of 26 
liver cancer. Efficient therapeutic approaches against HDV are absent.  27 
Design: Here, we combined an RNAi loss-of-function and small molecule screen to uncover 28 
host-dependency factors for HDV infection.  29 
Results: Functional screening unraveled the HIF-signaling and insulin resistance pathways, 30 
RNA polymerase II, glycosaminoglycan biosynthesis and the pyrimidine metabolism as virus-31 
hepatocyte dependency networks. Validation studies in primary human hepatocytes 32 
identified the CAD enzyme and estrogen receptor 1 (ESR1) as key host factors for HDV life 33 
cycle. Mechanistic studies revealed that the two host factors are required for viral replication. 34 
Inhibition studies using PALA and Fulvestrant, specific CAD and ESR1 inhibitors 35 
respectively, uncovered their impact as antiviral targets.  36 
Conclusion: The discovery of HDV host-dependency factors elucidates the pathogenesis of 37 
viral disease biology and opens therapeutic strategies for HDV cure. 38 
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SUMMARY BOX 52 
What is already known about this subject? 53 
• Chronic hepatitis D is the most severe form of viral hepatitis 54 
• Efficient therapeutic strategies are absent 55 
• Hepatitis D virus is a small HBV satellite virus 56 
• Knowledge about HDV-hepatocyte interactions is limited 57 
• HDV host-dependency factors are largely unknown 58 
What are the new findings? 59 
• A RNAi screen identified ESR1 and CAD as novel host factors for HDV infection 60 
• The inhibition of CAD restricts HDV infection through uridine depletion 61 
• ESR1 and CAD are functionally linked by transcriptional activation of gene expression 62 
• ESR1 and CAD inhibitors Fulvestrant and PALA, respectively, specifically inhibit HDV 63 
replication in a dose-dependent manner in human hepatocytes 64 
• CAD and ESR1 are previously undiscovered targets for antiviral therapies  65 
 66 
Significance of the study 67 
How might it impact on clinical practice in the foreseeable future? 68 
• The discovery of HDV host-dependency factors opens the door for novel therapeutic 69 
strategies against chronic hepatitis D – a major unmet medical need 70 
• Fulvestrant and PALA-like molecules are candidate compounds for HDV antivirals to 71 
enter preclinical development 72 
 73 
 74 
 75 
 76 
 77 
 78 
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INTRODUCTION 79 
Hepatitis delta virus (HDV) infects human hepatocytes and causes acute acerbation of liver 80 
disease in patients chronically infected with hepatitis B virus (HBV)[1]. Among HBV infected 81 
patients, 5 to 10% are co-infected with HDV[2]. HDV co- or sur-infection in HBV carriers 82 
induces more severe disease compared to infection with HBV alone. This includes a greater 83 
likelihood of experiencing liver failure and a more rapid progression to liver cirrhosis, with a 84 
markedly increased risk of developing hepatocellular carcinoma[3]. Consequently, chronic 85 
hepatitis D is considered as one of the most severe forms of viral hepatitis. Treatment with 86 
HBV nucleos(t)ide analogues is not effective at reducing HDV replication or disease. 87 
Moreover, the virus is only poorly controlled by the current IFN-based therapies[3] and to 88 
date, no treatment allows efficient cure of hepatitis D with eradication of the virus and its 89 
associated disease[4-6]. Thus, there is a major unmet medical need for curative therapies.  90 
HDV is a small, circular RNA HBV satellite virus related to plant viroids using HBV 91 
envelope proteins to assemble its infectious particles[1, 5, 6]. Consequently, it can only be 92 
propagated by HBV-infected hepatocytes producing HBV envelope proteins (HBsAg). The 93 
HDV genome is a circular 1.7 kb single-stranded negative-sense RNA molecule (for a review 94 
on HDV virology and pathogenesis, see [5]). The HDV life cycle starts with virus entry into 95 
hepatocyte after attachment to heparan sulfate proteoglycans (HSPG) at the cell surface[5, 96 
7]. As HBV and HDV share the same envelope proteins, they appear to share the same entry 97 
pathway and receptor(s), including the sodium taurocholate co-transporting polypeptide 98 
(NTCP) and Glypican 5 (reviewed in [5, 6, 8]). The HDV genome is then imported in the 99 
nucleus, and three types of RNAs are transcribed by the host RNA polymerase II: replication 100 
is initiated by synthesis of an anti-genomic RNA that serves as a template for the production 101 
of new HDV genomic RNA, and HDV mRNA from genomic RNA[5]. mRNA transcripts 102 
contain one unique open reading frame encoding the delta antigen (HDAg) which exists in 103 
two forms (small version S-HDAg and large version L-HDAg) which play differential roles in 104 
the HDV life cycle[5, 6]. Indeed, S-HDAg is essential to HDV replication, while prenylation of 105 
L-HDAg leads to the inhibition of HDV replication and is crucial for binding to HBV envelope 106 
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proteins and virion assembly[6]. In the nucleus, L-HDAgs bind to the de novo HDV genomic 107 
RNA to form a new ribonucleoprotein (RNPs), which is exported to the cytoplasm and 108 
interacts with HBsAgs at the endoplasmic reticulum to form new infectious virions, which are 109 
then secreted to propagate further rounds of HDV infection[6]. While the molecular virology 110 
of HDV has been elucidated, the role of host-dependency factors for HDV infection remains 111 
largely unknown[5]. 112 
A unique feature of HDV is the apparent lack of non-structural protein encoded by the 113 
viral genome (including viral polymerase), making it highly dependent of the host machinery 114 
for its replication. Targeting host factors is an emerging concept in the treatment of infectious 115 
diseases including hepatitis viruses[9-12]. Two host compounds targeting HDV factors have 116 
been developed up to clinical proof-of-concept: These include Myrcludex B, a small peptide 117 
targeting HBV/HDV entry factor NTCP and the prenylation inhibitor Lonafranib[4, 13, 14].  118 
Both compounds demonstrated a significant clinical antiviral effect in chronically infected 119 
patients[4, 13, 14], supporting the validity of the concept of host-targeting antivirals for HDV 120 
infection. However, data on long-term safety, potential resistance in subsets of patients and 121 
sustained virological response remain to be determined. Thus, complementary approaches 122 
targeting other host factors and/or steps of the HDV life cycle are needed for curative 123 
therapies. 124 
Taking advantage of our recently developed robust HDV infection system for the study 125 
of HDV-host factor interactions[7] combined with a dual screening approach, we aimed to 126 
uncover HDV host-dependency factors as antiviral targets.  127 
 128 
RESULTS 129 
A high-throughput RNAi loss-of-function screen uncovers hepatocyte host-130 
dependency factors required for HDV infection. To identify host factors required for HDV 131 
infection, we performed a high-throughput loss-of-function screen using the HDV-susceptible 132 
cell line Huh-106[7]. Since one key goal was the discovery of druggable host targets, we 133 
used a library comprising siRNAs targeting 7567 genes which have been selected as targets 134 
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for therapeutics, including kinases, proteases, phosphatases, G protein–coupled receptor, 135 
ion channels, ubiquitin ligases, protein involved in senescence, autophagy, DNA repair, and 136 
targetable nuclear receptors. Huh-106 cells were transfected with siRNAs pools 48 hours 137 
before inoculation with HDV (Figure 1A) with an optical immunostaining-based viral protein 138 
(HDAg) readout 7 days after infection. The silencing of expression of HDV host factor NTCP 139 
was used as functional positive control (Figure 1B-C). The results of the primary screen are 140 
presented in Table S1. 141 
 Using the hit selection algorithm described in Methods and Figure 1E, we identified 142 
191 host factor genes showing a robust correlation between gene silencing and level of HDV 143 
infection, moderate toxicity of gene-specific siRNA and their expression in the liver (Figure 144 
1D-E and Table S2). The threshold of hit selection (described in Figure 1E) was based on 145 
the functional effect of SLC10A1 silencing (approximately 45% decrease in HDV infection, 146 
Table S1). The hit rate of 191 genes corresponds to 2.5% of total genes, which is similar to 147 
screens for other virus host factor-dependency screens[15, 16].   148 
Functional pathway analysis using KEGG pathways identified a network of host 149 
factors belonging to HSPG biosynthesis, including EXT1 and EXT2 (Figure 2A-B). These 150 
genes encode two major exostosins, key HSPG-related enzymes exhibiting 151 
glycosyltransferase activities and involved in the elongation of HS chains[17]. Moreover, 152 
several subunits of the RNA polymerase II were identified in our screen (Figure 2B), 153 
including specific subunits such as POLR2G or POLR2I, encoding Rpb7 and Rpb9, which 154 
play key roles in the initiation of transcription and binding to DNA template for an accurate 155 
selection of the transcription start sites, respectively[18, 19]. The identification of HSPG 156 
enzymes and RNA polymerase II as known HDV-related pathways[5, 7] validates our 157 
approach for host factor discovery (Figure 2). Importantly, the screen identified several 158 
previously unknown HDV-related networks, such as the hypoxia inducible factor 1 alpha 159 
(HIF-1α) signaling pathway, known to enhance the replication of several RNA and DNA 160 
viruses such as Epstein-Barr virus (EBV) and HIV[20, 21]. Interestingly, the HIF-1α signaling 161 
pathway also plays a key role in hepatocarcinogenesis and liver tumor progression[22, 23] 162 
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through its ability to target the expression of oncogenic genes such as the proliferation-163 
specific transcription factor Forkhead box M1[24]. HIF-1α overexpression in HCC has been 164 
correlated with worse clinical outcomes and is considered as a poor prognosis factor and 165 
molecular target for liver disease therapy[24]. Interestingly, the highly significant scoring of 166 
insulin resistance-related pathways highlights the importance of hepatocyte metabolism as 167 
host-dependency factors on HDV infection (Figure 2).   168 
Finally, we identified several host factors involved in the biosynthesis of pyrimidine, 169 
including CANT1, ENTPD5, and CAD. 170 
 171 
The pyrimidine biosynthesis enzyme CAD is a key host factor for HDV infection and 172 
antiviral target in human hepatocytes. Given its high impact on HDV infection, functional 173 
relevance, liver expression and targetability, we focused on CAD, encoding the carbamoyl-174 
phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), an enzyme 175 
playing a key role in the pyrimidine biosynthesis (Table S2; Figure 2)[25]. Silencing of CAD 176 
led to a robust decrease in HDV infection (Figure 3A). CAD is a trifunctional enzyme 177 
catalyzing the first steps of pyrimidine biosynthesis[26]. Interestingly, CAD expression is 178 
known to be regulated by activated estrogen receptor 1 (ESR1) which binds to the 179 
transcription factor SP1[27], two other host-dependency factors uncovered by the RNAi 180 
screen (Figure 3A). These data suggest a key role of the pyrimidine biosynthesis pathway 181 
and its associated nuclear proteins for the HDV life cycle.  182 
We next investigated the functional role of CAD in HDV infection. We first performed 183 
additional silencing studies using individual CAD-specific siRNA. As shown in Figure 3B-D, a 184 
strong reduction of HDV RNA were observed after transfection of Huh-106 cells with the 4 185 
individual siRNAs composing the siRNA pool, validating the key role of CAD expression in 186 
HDV infection. Notably, CAD expression was not significantly affected by HDV infection 187 
(Figure 3E). 188 
Aiming to characterize the potential of CAD as an antiviral target, we synthetized a 189 
specific inhibitor of CAD, sparfosic acid or PALA (N-(Phosphonoacetyl)-L-aspartic acid)[26]. 190 
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PALA is an aspartic acid derivative, which inhibits the aspartate carbamoyltransferase 191 
activity of the enzyme. We then investigated the antiviral activity of PALA in HDV-infected 192 
Huh-106 cells. As shown in Figure 3F, PALA dose dependently inhibits HDV infection with an 193 
IC50 = 1.2 µM. Notably, a decrease in cell viability was observed after 7 days of culture. 194 
To validate this result in the most physiological model for HDV infection, we 195 
investigated the antiviral activity of PALA using HDV infection of primary human hepatocytes 196 
(PHH). Interestingly, while no toxicity was observed in PHH even at high doses (100 µM), the 197 
IC50 of PALA was slightly higher in PHH (Figure 3G), which may reflect differences in uridine 198 
pools and/or CAD expression in rapidly dividing Huh7-based cells versus non-dividing PHH 199 
in cell culture[28].  200 
To investigate the mechanism of action of CAD-HDV interaction, we performed a 201 
rescue experiment using PALA and uridine-supplemented medium. Northern blot detection of 202 
HDV genomic RNA in infected cells revealed that the addition of uridine in PALA-treated cells 203 
restored HDV infection, validating the functional relevance of pyrimidine pathway for HDV 204 
replication (Figure 4A). Notably, PALA at a concentration of 2.5 µM induced a strong 205 
decrease in HDV infection which was efficiently rescued by uridine treatment (Figure 4B-C). 206 
This dose was then selected for further functional studies. Importantly, no direct interaction 207 
was observed between CAD and the HDV antigens (Figure 4D). As the inhibition of 208 
pyrimidine pathway has been shown to stimulate the innate antiviral response with 209 
subsequent inhibition of viral propagation [29], we next assessed the expression of IFNB1 210 
following PALA treatment in Huh-106 cells. As shown in Figure 4E, no IFNB1 induction was 211 
observed after treatment with either PALA or Brequinar, targeting dihydroorotate 212 
dehydrogenase (DHODH), suggesting an absence of innate immune stimulation by 213 
pyrimidine inhibitors in hepatocyte-derived cells.  214 
To further validate the involvement of the biological function of CAD in HDV infection, 215 
cell culture medium was then complemented using either glutamine (Glu, the initial substrate 216 
of CAD), or dihydroorotate (DHO, the final product of CAD) (Figure 5A, as described in[25]). 217 
As shown in Figure 5B and Figure S1, while glutamine treatment had no effect on 218 
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intracellular HDV RNA, DHO treatment in PALA-treated cells restored HDV RNA to non-219 
treated levels, suggesting that PALA antiviral activity is linked to CAD physiological function. 220 
To map the replication steps targeted mediated by CAD and targeted by PALA, we 221 
performed Northern blot analyses of HDV RNA allowing to quantify the HDV genome and 222 
anti-genome in the presence or absence of PALA. As shown in Figure 5C, PALA treatment 223 
effectively decreased the levels of both HDV genomic and antigenomic RNAs. Moreover, this 224 
inhibition was already observed during the early stages of viral replication (Figure S2). These 225 
data demonstrate that PALA inhibits all the steps of HDV replication including the synthesis 226 
of antigenomic RNA (Figure 5C). 227 
Next, we performed kinetic studies adding PALA pre-, peri- and HDV post-infection 228 
(Figure 5D). PALA potently inhibited HDV infection given at any time before, during and 229 
following initiation of replication. Interestingly, the inhibitory effect was most pronounced 230 
when PALA was added prior or during initiation of replication.  Finally, to exclude effects on 231 
other steps of the early HDV life cycle, we studied the effect of PALA treatment on HDV 232 
binding to the Huh-106 cell surface. The absent effect on HDV binding further confirms HDV 233 
replication as the life cycle step targeted by PALA (Figure 5E).  234 
To test the specificity of the pyrimidine pathway for HDV infection, we treated HBV-235 
producing HepAD38 cells with PALA. As shown in Figure 5F, PALA did not modulate HBV 236 
antigen production as shown by an absent effect on HBeAg and HBsAg secretion. While 237 
tenofovir (TFV) treatment dose-dependently inhibited HBV replication, PALA had no effect on 238 
HBV DNA in the supernatant of HepAD38 cells (Figure 5G). Finally, the silencing of CAD 239 
expression did not affect HBV infection in HepG2-NTCP cells (Figure 5H). These results 240 
suggest that the pyrimidine/CAD pathway is relevant for HDV but not HBV replication. 241 
Collectively, our results identify CAD as a key HDV host factor involved in HDV replication 242 
and target for antiviral therapy. 243 
 244 
A small molecule screen uncovers ESR1 inhibitor Fulvestrant as host targeting agent. 245 
Next, we performed a small molecule screen using the Prestwick library, containing 1284 246 
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FDA-approved drugs (Figure 6A). Among the molecules exhibiting an antiviral activity against 247 
HDV we identified Fluvastatin and Cyclosporine A, two well described NTCP inhibitors (Table 248 
S3), confirming the validity of the screen. Interestingly, Ribavirin, a broad antiviral nucleoside 249 
analog[30] previously used for the treatment of chronic hepatitis C[31] exhibits a marked 250 
antiviral activity against HDV (Table S3). In the same vein, Nelfinavir, a protease inhibitor 251 
presenting anti-retroviral activity[32] was also identified in the drug screen (Table S3). 252 
Given our discovery of ESR1 as HDV host-dependency factor we next focused on 253 
ESR1-targeting agents. The library includes several agonists and antagonists of ESR1, as 254 
well as characterized targets for endocrine therapy in breast cancer[33]. Interestingly, the 255 
ESR1 antagonist Fulvestrant exhibited a marked, significant and dose-dependent antiviral 256 
effect against HDV, whereas Tamoxifen and Toremifen, two ESR1 modulators with 257 
estrogenic effects in the liver[34] increased HDV infection, validating the importance of ESR1 258 
in HDV infection (Figure 6B-C). Interestingly, a 48 h-treatment started after virus inoculation 259 
induced a marked decrease in HDV-infected cells (Figure 5D), suggesting an effect on HDV 260 
replication.  261 
Next, we aimed investigate the mechanism of action of the antiviral activity of 262 
Fulvestrant by investigating a functional link of ESR1 and CAD suggested by protein/protein 263 
interaction studies[27]. To address this question, CAD expression was analyzed in Huh-106 264 
cells and PHH in the presence or absence of the ESR1-antagonist (Figure 6E-G). As shown 265 
in Figure 6G, Fulvestrant treatment resulted in a loss of CAD expression in both Huh-106 cell 266 
line and PHH, suggesting that the antiviral activity of ESR1-inhibitor Fulvestrant is mediated 267 
by ESR1-mediated down-regulation of CAD expression, which in turn is required for HDV 268 
replication, confirming the previous observations with PALA.  269 
 Taken together, our dual screening approach uncovers the pyrimidine pathway and 270 
its associated and regulatory proteins as host factors for HDV infection and targets for 271 
antiviral therapy.  272 
 273 
 274 
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DISCUSSION 275 
Chronic hepatitis D is the most severe form of viral hepatitis and at present time no treatment 276 
allows robust viral clearance. Using a dual screening approach we identified ESR1 and CAD 277 
as host factors and antiviral targets for HDV infection. The functional impact of the pyrimidine 278 
biosynthesis for HDV replication is corroborated by (i) a marked decrease in HDV infection 279 
after CAD and ESR1 silencing; (ii) a significant antiviral effect of ESR1 and CAD inhibitors 280 
PALA and Fulvestrant and (iii) kinetic experiments mapping viral replication as the step of the 281 
viral life cycle mediated by these host factors and targeted by the antivirals (vi) validation 282 
studies in primary human hepatocytes.   283 
Whereas the molecular virology of HDV is well described, the molecular interactions 284 
between the virus and liver host factors are still largely unknown[5]. In mammalian cells, the 285 
pyrimidine biosynthesis pathway leads to the production of de novo nucleotides and plays a 286 
key role in RNA and DNA production, as well as protein glycosylation or cell membrane 287 
assembly[25]. Moreover, uridine nucleotides and derivatives regulate key physiological 288 
processes, such as lipid metabolism, regulation of normal central nervous system activity or 289 
modulation of reproduction[35], making this pathway a major actor of important metabolic 290 
processes. As a source of nucleotides for HDV RNA, this pathway is likely to be required for 291 
optimal virus replication. Moreover, as a key regulator of viral glycosylation[25], an alteration 292 
of this pathway may alter posttranslational modification of host or viral proteins, disrupting 293 
viral infection.  294 
CAD is a multifunctional enzyme exhibiting carbamoylphosphate synthetase, 295 
aspartate transcarbamoylase, and dihydroorotase activities catalyzing the three first steps of 296 
the pyrimidine biosynthesis pathway[36], playing a key role in HDV infection as such. The 297 
observed antiviral activity of the CAD-specific inhibitor PALA validates the importance of this 298 
factor and pathway in HDV infection. It is of interest to note that another enzyme of the 299 
pyrimidine biosynthesis pathway DHODH, which catalyzes the production of orotate from 300 
DHO, has been described as an antiviral target by small molecule GSK983[37]. Here, we 301 
confirmed that the CAD-mediated DHO and uridine starvation is responsible for the observed 302 
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antiviral effect (Figures 4 & 5). Interestingly, HSPG synthesis has been shown to be 303 
dependent on the pyrimidine synthesis pathway in a CAD-defective animal model[38]. 304 
However, we did not observe any effect of CAD inhibition on either HBV infection or HDV 305 
entry (Figure 5 E-H). While recent studies have suggested that the inhibition of pyrimidine 306 
biosynthesis can stimulate innate antiviral responses[29], no induction of IFN expression was 307 
observed in our model (Figure 4E). Thus, it is likely that the modulation of CAD activity or 308 
expression affects HDV infection through its classical enzymatic activity linked to pyrimidine 309 
metabolism, mainly affecting viral replication through uridine starvation, affecting both 310 
genomic and antigenomic HDV RNAs. In this context, our study suggests that the first steps 311 
of replication are particularly susceptible to PALA. These results are consistent with the 312 
timing of HDV RNA amplification, much more pronounced during the early phase of 313 
replication, before L-HDAg-mediated slow-down of replication[5].   314 
Among the genes regulating the pyrimidine pathway, we identified ESR1 as a HDV 315 
host-dependency factor and antiviral target. ESR1 is a nuclear hormone receptor expressed 316 
in the mammary gland and female reproductive track, but also in lung and liver[39]. In our 317 
mechanistic analyses, we show that ESR1 inhibition by Fulvestrant led to a decrease in CAD 318 
protein expression which most likely explains the antiviral effect of the molecule. 319 
Our screening strategy also identified small molecules exhibiting significant antiviral 320 
activity against HDV infection. Among them was found ribavirin, a nucleoside analog 321 
previously used for the treatment of chronic HCV infection[40]. Given its concentration in the 322 
primary screen (10 µM), HDV inhibition is most likely due to the ability of ribavirin to inhibit de 323 
novo synthesis of GTP as recently suggested as a possible mechanism for the inhibition of 324 
hepatitis E virus (HEV) replication in Huh7 cells (IC50 of 18.9 µM for GTP depletion; EC50 of 3 325 
µM for HEV replication[41]). However, clinical attempts to treat hepatitis D using ribavirin 326 
were largely unsuccessful[4].  327 
Collectively, we identified previously undiscovered pathways and host factors for HDV 328 
infection and antiviral targets. Host targeting agents are a promising approach for the 329 
development of new antiviral treatments, notably because they limit the emergence of 330 
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resistant variants[8-10, 42]. In particular for RNA viruses, which do not integrate into the 331 
genome, host targeting agents hold promise for viral cure[43]. Indeed, in chronic HCV 332 
infection antibodies targeting a viral host entry factor Claudin-1 cure viral infection in a state-333 
of-the-art mouse model[12], and a miRNA-122 antagonist has been shown to cure chronic 334 
HCV infection in monotherapy in a subset of patients[44]. Two host compounds targeting 335 
HDV factors have been developed up to clinical proof-of-concept: these include Myrcludex B, 336 
a small peptide targeting HBV/HDV entry factor NTCP and the prenylation inhibitor 337 
Lonafranib[4, 13, 14]. In randomized clinical trials, both compounds demonstrated a 338 
significant and robust antiviral effect in chronically infected patients[4, 13, 14], supporting the 339 
validity of the concept of host-targeting antivirals for HDV infection. However, long-term 340 
safety, potential resistance in subsets of patients and data on sustained virological response 341 
remain to be determined. The discovery of novel host factors described in this study may 342 
overcome these limitations by complementary, safer and more efficient approaches. 343 
Compounds targeting essential host factors of the viral replication step may be conceptually 344 
superior to entry or prenylation inhibitors by targeting the most vulnerable step of the viral life 345 
cycle. Indeed, viral replication is the target of many effective clinically licensed antiviral 346 
therapies such as nucleoside analogues for HBV infection or polymerase/protease inhibitors 347 
for HIV and HCV infection.   348 
A theoretical disadvantage of HTA is their putative adverse effects on physiological 349 
processes mediated by the host factors. In this context, given that an HDV treatment will 350 
occur in a context of diseased liver, assessment of safety will be a major parameter in 351 
development. In this regard, it is of interest to note that pyrimidine synthesis inhibitors, such 352 
as Leflunomide or Teriflunomide, are currently used for the treatment of rheumatoid arthritis 353 
and multiple sclerosis[45, 46]. The safety profile of these compounds suggests that 354 
pyrimidine biosynthesis is a targetable pathway for antiviral strategies. Indeed, the FDA-355 
approved Leflunomide, targeting DHODH, induces uridine starvation at concentrations 356 
similar to PALA concentrations we used in this study (0-100 µM)[47]. Although detailed 357 
toxicity analyses in animal model and human tissues will be required to assess the 358 
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therapeutic window of PALA, the dose-response effects of Leflunomide suggests that PALA 359 
doses required to inhibit HDV infection are most likely in a range that will have an acceptable 360 
clinical safety profile.  361 
In conclusion, by uncovering key host factors for HDV infection our results 362 
significantly improve the understanding of the HDV life cycle and contribute to the 363 
development of novel antiviral strategies for HDV cure.  364 
 365 
 366 
MATERIAL AND METHODS 367 
Human subjects. Human serum from patients with chronic HBV/HDV infection followed at 368 
the Strasbourg University Hospitals, Strasbourg, France was obtained with informed consent. 369 
PHH were obtained from liver tissue from patients undergoing liver resection for liver 370 
metastasis at the Strasbourg University Hospitals with informed consent. Protocols were 371 
approved by the local Ethics Committee of the Strasbourg University Hospitals (CPP) and 372 
the Ministry of Higher Education and Research of France (DC 2016 2616). 373 
 374 
Cell lines and human hepatocytes. Huh-106[7], HepAD38[7] and HepG2-NTCP[7] cells 375 
have been described. PHH were isolated and cultured as described[48].  376 
 377 
Key Reagents. Fulvestrant (I4409), DL-dihydroorotic acid (DHO, D7003), L-glutamine 378 
(59202C), uridine (U3003), and tenofovir (1643601) were purchased from Sigma-Aldrich® 379 
(Merck). Sparfocid acid (L-Aspartic acid, N-(phosphonoacetyl)-, disodium salt (9CI) or PALA, 380 
NSC: 224131) was first obtained from the Drug Synthesis and Chemistry Branch, 381 
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National 382 
Cancer Institute, National Institute of Health, Bethesda, Maryland, USA. For further analyses, 383 
PALA was synthetized at the Institute of Chemistry, University of Strasbourg, as described in 384 
Supplementary Material and Methods. PreS1 peptide was synthetized by Bachem[7].  385 
 386 
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HDV and HBV production and infection. The production of recombinant HDV and HBV 387 
infectious virus as well as the protocol for HDV infection of Huh-106 cells and PHHs and for 388 
HBV infection of HepG2-NTCP cells have been described[7, 49, 50]. A detailed protocol is 389 
presented in Supplementary Material and Methods.  390 
 391 
RNAi loss-of-function and small molecule screens. Screening was performed at the High 392 
Throughput Screening platform of the Institut de Génétique et de Biologie Moléculaire et 393 
Cellulaire (IGBMC) in Illkirch, France. The Human ON-TARGETplus “Druggable Genome” 394 
siRNA Library was used for gene expression silencing. For the small molecule screen, the 395 
Chemical Library® containing 1280 FDA-approved molecules was obtained from Prestwick. 396 
Detailed information about both screening strategies as well as the algorithm for selection of 397 
HDV-dependency candidates are presented in Supplementary Material and Methods.   398 
 399 
Validation of CAD as a HDV host factor using individual siRNAs. Huh-106 cells were 400 
reverse-transfected with the 4 individual siRNAs from the siCAD pool, a pool of siRNA 401 
targeting SLC10A1 (siNTCP), or a non-targeting siRNA control (siCtrl) using Lipofectamin 402 
RNAi max as described[7, 50]. Gene expression was assessed, two days after transfection, 403 
by Western blot detection of CAD protein using a Rabbit monoclonal anti-CAD antibody 404 
(Abcam ab40800) as previously described[7, 50]. β-actin expression was assessed as a 405 
loading control using a mouse monoclonal anti-β-actin antibody (Sigma, A5441). Two days 406 
after transfection, cells were infected by HDV and infection was assessed after 7 days as 407 
described in Supplementary Material and Methods. 408 
 409 
Statistical analysis. All experiments were performed at least twice in an independent 410 
manner. Statistical analyses were performed using a two-tailed Mann-Whitney U test unless 411 
otherwise stated; p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) were considered statistically 412 
significant. Significant p-values are indicated by asterisks in the individual figures and figure 413 
legends. The number of biological replicates is indicated in the figure legends (n).  414 
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Additional methodological information are available in Online Supplementary Material.  416 
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FIGURE LEGENDS  576 
 577 
 578 
 579 
Figure 1. Identification of host-dependency factors for HDV infection using a high-580 
throughput RNAi screen. A. Approach with flow chart of the screen. NTCP-overexpressing 581 
Huh7 cells (termed Huh-106) were transfected with pools of 4 siRNAs per target of the 582 
Dharmacon “Druggable genome” library 48 h before HDV infection. Infection was assessed 583 
after 7 days by immunofluorescence. Each siRNA pool was tested in triplicate. As controls, 584 
Huh-106 cells were transfected with a non-targeting siRNA control (siCtrl), siRNA targeting 585 
SLC10A1 (siNTCP) and PLK1 (siPLK1, lethal for the cells) expression. Representative 586 
images of HDV infection in Huh-106 cells from the primary screen are shown in B. As 587 
readout for infection, cells were stained with an anti-HDAg antibody and cell nuclei were 588 
stained with DAPI. C. General effect of the siNTCP on HDV infection at the screen level. 589 
Results are expressed as means ± SD % HDV positive cells from siCtrl-treated cells (n = 590 
318) and siNTCP-treated cells (n = 265). *** pvalue < 0.001 (unpaired Student’s t-test). D. 591 
Distribution of host-factor candidates according to their inhibitory effect on HDV infection. 592 
The top 5% (% HDV positive cells < 8.3) were selected as candidates for further work-up. E. 593 
Selection of candidate genes from the primary screen. From the 311 genes inducing a > 45% 594 
decrease in HDV infection after silencing, candidate genes were selected depending on their 595 
robustness (p-value & FDR < 0.05), their expression in the liver (Illumina Body Map tool) and 596 
their toxicity. Toxicity was evaluated as the percentage of viability compared to the siCtrl, 597 
quantified by counting the DAPI-positive nuclei in the wells at the end of infection. From the 598 
194 selected candidates, RNF130 was present twice (subset 8 and subset 10) and 2 599 
pseudogenes (tAKR/AKR1C6P and LOC402164) were removed. 191 candidates (top 2.5%) 600 
were further worked-up.  601 
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 602 
Figure 2. Pathway analysis of HDV host factors identified within the RNAi screen. The 603 
identified host genes were subjected to functional enrichment pathway analysis through 604 
ToppGene Suite (https://toppgene.cchmc.org) using Kyoto Encyclopedia of Genes and 605 
Genomes (KEGG) database. Pathways scoring at a FDR value of < 0.05 were considered 606 
significant. A. Representation of the number of genes and FDR values of different KEGG 607 
pathways significantly enriched within the primary siRNA screen candidates. B. Individual 608 
genes contributing to the enrichment of the significant KEGG pathways were further 609 
analyzed for protein-protein interactions using STRING database. Interaction networks were 610 
represented using Cytoscape 3.6.0.  611 
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 612 
Figure 3. CAD is a key host factor required for HDV infection. A. Functional validation of 613 
host factors belonging to the pyrimidine biosynthesis using perturbation studies. Results are 614 
presented as means ± SD % HDV infection compared to control siRNA (siCtrl, set at 100%) 615 
from three independent screens (n = 9, primary screen and two validation screens performed 616 
in triplicate). *** pvalue < 0.001 (unpaired Student’s t-test compared to siCtrl samples). B-D. 617 
CAD is required for HDV infection. Huh-106 cells were reverse-transfected with 4 individual 618 
siRNAs targeting CAD mRNA or with the pool of 4 siRNAs. Silencing efficacy was assessed 619 
by Western blot after two days (B). One representative experiment is shown. Cells were then 620 
infected with HDV and virus infection was assessed after 7 days by qRT-PCR. Results are 621 
expressed as means ± SEM % HDV infection compared to siCtrl (set at 100%) from three 622 
independent experiments (n = 8) (C). Alternatively, HDV infection was assessed by 623 
immunofluorescence using a patient-derived anti-HDAg antibody (D). One representative 624 
experiment using the pool of siCAD is shown. E. HDV infection has no effect on CAD 625 
expression in PHH. PHH were treated with preS1 peptide (preS1) or a peptide control (Ctrl) 626 
for one hour prior to infection with HDV for seven days. Results are expressed as means ± 627 
SD % HDV infection (assessed by HDV RNA levels) or CAD expression compared to control 628 
peptide-treated cells (Ctrl, set at 100%) from four independent experiments (n = 8). F-G. The 629 
CAD inhibitor PALA dose-dependently inhibits HDV infection in Huh-106 cells (F) and PHH 630 
(G). Cells were treated with PALA at the indicated concentrations 24 h before infection with 631 
HDV. Cells were then cultured for 7 days in presence of PALA. HDV infection was assessed 632 
by qRT-PCR. Cell viability was assessed by Presto Blue. Results are expressed as means ± 633 
SD % HDV infection or cell viability compared to untreated cells (0, set at 100%) from three 634 
independent experiments (Huh-106, F, n = 9) or as means ± SEM % HDV infection or cell 635 
viability from three independent experiments (PHH, G, n = 8).  636 
  637 
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Figure 4. Characterization of CAD-HDV functional interaction. A-B-C. Uridine 638 
complementation restores HDV infection in PALA-treated cells. Huh-106 cells were treated 639 
with PALA (1 µM or 10 µM) in presence of absence of 30 µM uridine 24 h prior to infection 640 
with HDV and compound treatment was maintained for 7 days. HDV infection was assessed 641 
by Northern blot (A). HDV+ corresponds to approximately 5.107 HDV RNA genome 642 
equivalents extracted from HDV particles produced in Huh7 cells. rRNA corresponds to 643 
ribosomal RNA. One representative experiment is shown. Alternatively, Huh-106 cells were 644 
treated with PALA 2.5 µM in presence of absence of 30 µM uridine. HDV infection was 645 
assessed after 7 days by IF (B) or qRT-PCR (C) Results are expressed as means ± SEM % 646 
HDV infection compared to HDV-infected untreated cells (Ctrl, set at 100%) from three 647 
independent experiments (n = 6). D. Absent direct interaction between HDV antigens and 648 
CAD. Huh-106 were transfected with pSVL(D3) plasmid encoding the HDV genome. Three 649 
days after transfection, cells were lysed and HDAg-specific co-IP was performed using an 650 
anti-HDAg antibody (Delta) or with a control antibody (Ctrl). HDV antigens and CAD 651 
expression in the original cell lysate (Input), in Flow-through control samples (FT) and in IP 652 
eluates (IP) were assessed by Western blot. One experiment is shown. E. No IFN induction 653 
after inhibition of pyrimidine biosynthesis in Huh-106 cells. Huh-106 cells were treated with 654 
Brequinar or PALA at the indicated concentrations. Alternatively, Huh-106 cells were 655 
reverse-transfected with Poly(I:C) (100 ng). Cells were then lysed every day for three days, 656 
and IFNB1 expression was assessed by qRT-PCR. Results are expressed as means ± SD 657 
relative IFNB1 expression (log10) compared to untreated or non-transfected cells (0, all set 658 
at 1) from three independent experiments (n = 6).  659 
  660 
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 661 
Figure 5. PALA specifically inhibits HDV replication by targeting CAD biological 662 
function. A. Schematic representation of reactions catalyzed by CAD enzyme. Glu: 663 
glutamine; Carbomoyl-p: carbomoyl phosphate; Pi: inorganic phosphate; CA: Carbamoyl 664 
aspartic acid; DHO: dihydroorotate; UMP: uridine mono-phosphate. B.  DHO treatment 665 
restores HDV infection in PALA-treated cells. Huh-106 cells with treated with PALA 2.5 µM 666 
and infected with HDV in presence or absence of L-glutamine (Glu) or DHO at the indicated 667 
concentrations. Infection was assessed after 7 days by Northern blot detection of HDV 668 
genomic RNA. rRNA corresponds to ribosomal RNA. One experiment is shown. C. PALA 669 
inhibits both HDV genomic and antigenomic production. Huh-106 cells were treated with 670 
PALA 2.5 µM 24 h prior to infection with HDV. HDV genomic and antigenomic RNAs were 671 
detected by Northern blot using specific probes 7 days after infection. HDV+ corresponds to 672 
approximately 5.107 HDV RNA genome equivalents extracted from HDV particles produced 673 
in Huh7 cells. One experiment is shown. D. Kinetics of HDV infection by PALA. Huh-106 674 
cells were pretreated with PALA at 2.5 µM and infected with HDV (conditions P#1 and P#2). 675 
Cells were then cultured in presence of PALA for 48 h (P#1) or for 7 days (P#2) in presence 676 
or absence of uridine (30 µM). Alternatively, Huh-106 cells were infected with HDV with no 677 
PALA pre-treatment (P#3). 16 h after viral inoculation, cells were cultured in presence of 678 
PALA 2.5 µM with or without uridine (30 µM). HDV infection was assessed after 7 days by 679 
qRT-PCR. Results are expressed as means ± SEM % HDV infection compared to HDV-680 
infected untreated cells (Ctrl, set at 100%) from three independent experiments (n = 6). E. 681 
PALA does not affect HDV binding. Huh-106 cells were culture for 24 h à 16°C in presence 682 
of HDV particles which were pre-treated or not with heparin (30 µg/mL). HDV binding was 683 
measured by qRT-PCR quantification of total HDV RNA bound to cells after 24h. Results are 684 
expressed as means ± SD % HDV binding relative to control untreated cells (Ctrl, set at 685 
100%) from three independent experiments (n=9). F-H. CAD inhibition or silencing does not 686 
affect HBV infection and replication. F. HBV-producing HepAD38 cells were treated with 687 
PALA (10 µM) for three days. HBeAg and HBsAg secretion in culture supernatant was then 688 
quantified by chemiluminescent immunoassay (CLIA). Cell viability was assessed by Presto 689 
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Blue. Results are expressed as means ± SEM % HBeAg production, HBsAg production or 690 
cell viability compared to untreated cells (0 µM, all set at 100%) from three independent 691 
experiments (n = 6). G. HepAD38 cells were treated with either tenofovir (TFV) or PALA at 692 
the indicated concentrations for three days. HBV replication was assessed by quantification 693 
of HBV DNA copies in the supernatant of treated cells by qPCR. Results are expressed as 694 
means ± SD % HBV DNA in the supernatant or cell viability compared to untreated cells (Ctrl, 695 
all set at 100%) from three independent experiments (n = 9) H. HepG2-NTCP cells were 696 
reverse-transfected with siCAD or siCtrl for two days prior to infection with HBV. HBV 697 
infection was assessed after 10 days by quantification of HBeAg and HBsAg production 698 
(CLIA). Results are expressed as means ± SD % CAD expression, HBeAg production or 699 
HBsAg production compared to siCtrl-transfected cells (siCtrl, all set at 100%) from three 700 
independent experiments (n = 6). 701 
  702 
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 703 
Figure 6. ESR1 inhibitor Fulvestrant inhibits HDV replication by suppression of CAD 704 
expression. A. Small molecule screen flow chart. Huh-106 cells were treated with individual 705 
compounds belonging to the Prestwick Chemical library (10 µM) one day prior to infection 706 
with HDV. Infection was assessed after 7 days by immunofluorescence. Every compound 707 
was tested in triplicate. B. ESR1 modulators affect HDV infection. From the primary screen, 708 
Fulvestrant (an ESR1 inhibitor) from the one hand, Tamoxifen and Toremifen from the other 709 
hand (two agonists/modulators of ESR1) exhibited antiviral or proviral activity against HDV, 710 
respectively. Results are presented as means ± SD % HDV infected cells (n = 3). C. 711 
Fulvestrant dose-dependently inhibits HDV infection. Huh-106 cells were treated with 712 
Fulvestrant at the indicated concentrations and then infected with HDV for seven days. 713 
Results are expressed as means ± SD % HDV infected cells from three independent 714 
experiments (n = 9). D. Short Fulvestrant treatment for 48 h following virus inoculation 715 
inhibits HDV infection. Huh-106 cells were infected with HDV and then treated with 716 
Fulvestrant (10 µM) or DMSO for 48 h. Cells were then culture in absence of drug and 717 
infection was assessed after 7 days by IF. One representative experiment is shown. E. 718 
Fulvestrant antiviral activity is associated with slight cytotoxicity. Cell viability was assessed 719 
after 48 h and after 7 days by Presto blue. HDV infection was assessed after 7 days by qRT-720 
PCR. Results are expressed as means ± SD % HDV infection (HDV RNA) or cell viability 721 
compared to untreated HDV-infected cells (Ctrl, set at 100%) from three independent 722 
experiments (n = 9). F. Fulvestrant antiviral activity in PHH. PHH were infected with HDV and 723 
then treated with Fulvestrant for 48 h at the indicated concentrations. Results are expressed 724 
as means ± SD % HDV infection (HDV RNA) or cell viability compared to untreated HDV-725 
infected PHH (Ctrl, set at 100%) from two independent experiments (n = 6). G. Fulvestrant 726 
inhibits CAD expression. Huh-106 cells and PHH were treated with Fulvestrant (Fulv, 10 µM) 727 
or DMSO for 72h. CAD expression was assessed by Western blot.  728 
